Breed · Dog

Italian Greyhound: adverse event reports

FDA breed label "Greyhound - Italian" · single-breed animals only

Read this first · FDA's caveat, in its words

An API dataset query result cannot be used to estimate the risk associated with the product or compare one drug or device product with another. When looking at the results, be aware that there is no certainty that the reported drug or device caused the adverse event. This dataset should not be the sole source of information for clinical decision-making or other assumptions about the safety or effectiveness of a product. The adverse event may have been related to an underlying disease, other drugs used at the same time or other non-drug related sources. FDA Center for Veterinary Medicine

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.

Not veterinary advice. This site lists what was reported to FDA. For an animal that is unwell, contact a veterinarian.

980reports, 1991–20260.1% of dog reports

26reports, 12 months to March 202646 in the 12 months before

39.5%classed serious, as reportedall dogs: 38.3%

15%name milbemycin oxime + spinosadall dogs: 13.1%

980 adverse event reports received by FDA describe an animal recorded as Italian Greyhound (FDA breed label "Greyhound - Italian"). That is 0.1% of all reports about dogs. Crossbred animals are not counted here, only reports that give this single breed.

26 reports arrived in the 12 months to March 2026, down 43% from 46 in the 12 months before. A breed's count mostly mirrors how common the breed is; registration and ownership figures by breed are not public data, so no per-animal rate can be given.

By active ingredient, the drugs named most often are milbemycin oxime + spinosad, ivermectin + pyrantel pamoate and spinosad. Milbemycin Oxime + Spinosad is named in 15% of this breed's reports, about the same share as in reports about all dogs (13.1%).

The terms listed most often are vomiting (25.7%), emesis (9.9%) and lethargy (9.2%). Vomiting appears in 25.7% of reports, a larger share than in all dog reports (19.7%). 39.5% of reports stating seriousness were classed as serious, against 38.3% for dogs overall.

Drugs named most often, by active ingredient

Active ingredients recorded for the drug	Reports	Share of Italian Greyhound reports	Share of all dog reports
Milbemycin Oxime + Spinosad	147	15%	13.1%
Ivermectin + Pyrantel Pamoate	110	11.2%	14.9%
Spinosad	87	8.9%	5.8%
Moxidectin	59	6%	5%
Carprofen	47	4.8%	4.8%
Fluralaner	45	4.6%	6.7%
Milbemycin Oxime	42	4.3%	3%
Afoxolaner	34	3.5%	5.7%
Lufenuron + Milbemycin Oxime	33	3.4%	2.7%
Selamectin	32	3.3%	3%
Milbemycin Oxime + Praziquantel	27	2.8%	3.1%
Maropitant	25	2.6%	1.2%
Cyclosporine	23	2.3%	1.5%
Pyrantel Pamoate + Sarolaner	22	2.2%	5.1%
Imidacloprid + Moxidectin	19	1.9%	1.3%
Sarolaner	19	1.9%	1.7%
Meloxicam	16	1.6%	0.8%
Prednisone	16	1.6%	0.9%
Febantel + Praziquantel + Pyrantel Pamoate	15	1.5%	0.7%
Oclacitinib	15	1.5%	2.9%

Ordered by report count. Differences from the species column often come from body size (which drugs a breed is prescribed) and from how common the breed was in the years a drug sold most. FDA states that these data cannot be used to estimate risk or to compare one product with another. Brand and manufacturer names are masked by FDA in these records.

Signs listed in reports

share of Italian Greyhound reports listing the termall dog reports

Vomiting25.7%252
Emesis[vomiting]9.9%97
Lethargy[unusually tired or inactive]9.2%90
Diarrhoea[diarrhea]8.3%81
Seizure NOS[seizure, type not specified]5.8%57
Anorexia[not eating]5.7%56
Ataxia[unsteady, uncoordinated movement]4.4%43
Lack of efficacy (endoparasite) - hookworm[the product did not have the expected effect: hookworms]4.4%43
Lack of efficacy (ectoparasite) - flea[the product did not have the expected effect: fleas]4%39
Convulsion[seizure]3.8%37
Depression[dull, quiet or withdrawn]3.8%37
Elevated alanine aminotransferase (ALT)[a liver enzyme above the normal range]3.8%37
Lack of efficacy - NOS[the product did not have the expected effect]3.1%30
Fever2.8%27
Shaking2.8%27
Leucocytosis NOS[high white blood cell count]2.3%23
Elevated serum alkaline phosphatase (SAP)[a liver and bone enzyme above the normal range]2.2%22
Ineffective, heartworm larvae[legacy FDA term: the product did not have the expected effect (heartworm larvae)]2.2%22
Not eating2.1%21
Pruritus[itching]2.1%21
Behavioural disorder NOS[behaviour change, type not specified]2%20
Trembling2%20
Urticaria[hives]2%20
Weight loss2%20
Death by euthanasia[the animal was euthanized]1.9%19

Age and weight

Age of the animal

Under 1 year10.5%103

1 to 3 years25.6%251

4 to 7 years29.4%288

8 to 11 years19.1%187

12 years and over11.6%114

Age not given3.8%37

Weight of the animal

Under 5 kg (11 lb)25.8%253

5 to 9.9 kg (11–22 lb)60.6%594

10 to 24.9 kg (22–55 lb)9.4%92

25 to 44.9 kg (55–99 lb)0.9%9

45 kg and over (99 lb+)0.1%1

Weight not given3.2%31

Coloured bar: Italian Greyhound reports. Grey bar: all dog reports.

Trend and outcomes

Reports by month FDA received them. The newest months are incomplete because FDA posts reports with a delay of three to six months.

Outcome recorded in the report

Recovered/Normal33.6%329

Recovered with Sequela1.6%16

Ongoing14%137

Died1.5%15

Euthanized1.3%13

Outcome Unknown19.5%191

Beside all dogs

Measure	Italian Greyhound	All dogs
Reports	980	985,675
Latest 12 months	26	53,292
Classed serious, of reports stating it	39.5%	38.3%
Death or euthanasia recorded, per 1,000 reports	28.6	55

Questions about Italian Greyhound reports

How many FDA adverse event reports involve Italian Greyhounds?

980 reports through March 2026, 0.1% of reports about dogs; 26 in the latest 12 months.

Which drugs are named most often in Italian Greyhound reports?

By active ingredient: milbemycin oxime + spinosad (147), ivermectin + pyrantel pamoate (110), spinosad (87), moxidectin (59) and carprofen (47). Brands are masked in the public data.

What signs are reported most for this breed?

vomiting (25.7%), emesis (9.9%), lethargy (9.2%), diarrhoea (8.3%) and seizure NOS (5.8%).

Is the Italian Greyhound more sensitive to certain drugs?

Report counts cannot answer that. They show what was reported, not what a drug did, and they are not adjusted for how many Italian Greyhound animals exist or were treated. Breed-related drug sensitivities that are established are described on FDA-approved labels; a veterinarian is the person to ask about an individual animal.

Why are crossbreds not included?

FDA records crossbred animals with one or more component breeds. Counting them under each component would double count, so breed pages use single-breed reports only. Crossbreds remain in the species totals.

How do I report a problem?

Call the drug company using the number on the label, or send Form FDA 1932a to FDA. See the guide on how to report.

Where this comes from. Counts are built from the openFDA Animal & Veterinary adverse event bulk files released 28 Sep 2026, which hold reports FDA's Center for Veterinary Medicine received through 31 Mar 2026. openFDA masks brand and manufacturer names in these files, so drugs are counted by the active ingredients each record discloses and no figure is attributed to a brand, application or company. Ingredient names, and the separate reference lists of approved products, follow the FDA Green Book as of 1 Oct 2026. Breed names are FDA's labels rearranged into everyday order ("Greyhound - Italian" becomes "Italian Greyhound"). No report text, lot numbers or reporter details are published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.